GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Total Current Liabilities

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Total Current Liabilities : HK$126.78 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. ImmuneOnco Biopharmaceuticals (Shanghai)'s total current liabilities for the quarter that ended in Dec. 2023 was HK$126.78

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Liabilities Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Liabilities Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23
Total Current Liabilities
3,034.02 57.78 126.78

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Current Liabilities Get a 7-Day Free Trial - 57.78 80.93 126.78 -

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=20.229+70.415
+Other Current Liabilities+Current Deferred Liabilities
=36.134+0
=126.78

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=20.229+70.415
+Other Current Liabilities+Current Deferred Liabilities
=36.134+0
=126.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Total Current Liabilities
Comparable Companies
HKSE:09966 HKSE:06660 HKSE:09969 HKSE:01952 HKSE:02105 HKSE:02315 HKSE:06955 HKSE:06855 HKSE:02696 HKSE:06826 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Gba Fund Investment Limited 2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Tian Wenzhi 2501 Other
Lav Immon Hong Kong Limited 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines